APOGEE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.3 USD | -1.30% |
|
+3.98% | +90.77% |
| May. 13 | Apogee Therapeutics' Q1 Net Loss Widens | MT |
| May. 13 | Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 1,416 | 3,116 | - | - |
| Enterprise Value (EV) 1 | 1,020 | 2,843 | 2,701 | 3,116 |
| P/E ratio | -8.32 x | -19.7 x | -16.5 x | -13.2 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | - | 46.6 x | 27.6 x | 26.4 x |
| EV / FCF | -13.6 x | -22 x | -18.1 x | -18.8 x |
| FCF Yield | -7.34% | -4.54% | -5.54% | -5.31% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 50,674 | 58,456 | - | - |
| Reference price 2 | 27.94 | 53.30 | 53.30 | 53.30 |
| Announcement Date | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | - | - | - | - |
| EBITDA 1 | - | 61 | 98 | 118 |
| EBIT 1 | -93 | -163.2 | -209.8 | -291.2 |
| Operating Margin | - | - | - | - |
| Earnings before Tax (EBT) 1 | -83.98 | -154.2 | -210.2 | -282.8 |
| Net income 1 | -83.98 | -150.4 | -200.6 | -282.8 |
| Net margin | - | - | - | - |
| EPS 2 | -3.360 | -2.700 | -3.240 | -4.050 |
| Free Cash Flow 1 | -74.93 | -129 | -149.5 | -165.5 |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Announcement Date | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | -38.15 | 12 | 18 | 25 | - | - |
| EBIT 1 | - | -18.88 | -24.3 | -37.16 | -38.18 | -39.58 | -41.63 | -44.7 | -43.15 | -45.1 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -18.88 | -20.84 | -31.74 | -32.09 | -36.07 | -39.98 | -45.95 | -45 | -48 |
| Net income 1 | -12.52 | -18.88 | -20.84 | -31.74 | -32.09 | -35.19 | -38.61 | -43.76 | -39.65 | -41.5 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -2.510 | -3.780 | -0.5100 | -0.3200 | -0.6400 | -0.6267 | -0.6733 | -0.7683 | -0.6650 | -0.6950 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 6/22/23 | 8/28/23 | 11/13/23 | 3/5/24 | 5/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 395 | 273 | 415 | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | -74.9 | -129 | -150 | -166 |
| ROE (net income / shareholders' equity) | - | -31.5% | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share 2 | - | -2.590 | -2.770 | - |
| Capex 1 | 0.17 | 0.85 | 1.6 | 3 |
| Capex / Sales | - | - | - | - |
| Announcement Date | 3/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
53.3
USD
Average target price
84.83
USD
Spread / Average Target
+59.16%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +90.77% | 3.16B | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- APGE Stock
- Financials Apogee Therapeutics, Inc.